Screw loosening (SL) is a common complication following lumbar interbody fusion (LIF), particularly for degenerative lumbar disease. This study investigated the risk factors for SL following LIF for degenerative lumbar disease and examined the clinical relevance of SL. A PROSPERO-registered systematic search was conducted in the ScienceDirect, PubMed, Google Scholar, Epistemonikos, and Cochrane databases to identify longitudinal studies up to October 2024. Degenerative lumbar diseases included stenosis, spondylolisthesis, and disc herniation. Assessed risk factors were Cobb angle, lumbar lordosis (LL) angle, screw length, fixation to the sacrum, fused levels, and Hounsfield units (HU). Twenty-two studies involving 3,689 participants (56%±5% female; mean age, 61.95±9.55 years) and 17,722 lumbar screws were analyzed. Overall, 10%±2% of screws exhibited loosening in 29%±5% of patients, with 5%±2% undergoing revision surgery. Patients with SL (SL group) and those without SL (non-SL group) had similar sex distribution, body mass index, and comorbidities. The SL group had higher Visual Analog Scale scores for back pain (mean difference [MD], 0.75; 95% confidence interval [CI], 0.42–1.07; p<0.001) and Oswestry Disability Index scores (MD, 3.34; 95% CI, 0.49–6.20; p=0.02), indicating the clinical relevance of SL. The SL group exhibited significantly higher Cobb angle (MD, 2.42; 95% CI, 0.36–4.49; p=0.02), lower LL angle (MD, −3.67; 95% CI, −6.33 to −1.01; p=0.01), and shorter screw length (MD, −1.62; 95% CI, −2.78 to −0.45; p=0.01). Fixation to the sacrum, increased fused levels, and decreased HU were significant risk factors. The area under the curve for HU was 0.80 (0.77–0.84), with a sensitivity of 0.74 (0.67–0.81) and specificity of 0.76 (0.66–0.84), underscoring notable prognostic value. Patients with SL exhibited higher Cobb angles, lower LL angles, and shorter screws. Fixation to sacrum, increased fused levels, and decreased HU were significant risk factors for SL (PROSPERO ID: CRD42024563780).

The current gold-standard management of hyperglycemia in individuals with type 1 diabetes mellitus (T1DM) is insulin therapy. However, this therapy is associated with a high incidence of complications, and delaying the onset of this disease produces a substantially positive impact on quality of life for individuals with a predisposition to T1DM, especially children. This review aimed to assess the use of gamma-aminobutyric acid (GABA) to delay the onset of T1DM in children. GABA produces protective and proliferative effects in 2 ways, β cell and immune cell modulation. Various in vitro and in vivo studies have shown that GABA induces proliferation of β cells, increases insulin levels, inhibits β-cell apoptosis, and suppresses T helper 1 cell activity against islet antigens. Oral GABA is safe as no serious adverse effects were reported in any of the studies included in this review. These findings demonstrate promising results for the use of GABA treatment to delay T1DM, specifically in genetically predisposed children, through immunoregulatory effects and the ability to induce β-cell proliferation.